Breaking News Instant updates and real-time market news.

MXL

MaxLinear

$17.90

0.59 (3.41%)

16:45
08/07/18
08/07
16:45
08/07/18
16:45

MaxLinear reports Q2 EPS 34c, consensus 31c

Reports Q2 revenue $101.5M, consensus $103.7M.

  • 07

    Aug

  • 14

    Aug

  • 16

    Aug

  • 04

    Sep

MXL MaxLinear
$17.90

0.59 (3.41%)

06/11/18
ROTH
06/11/18
DOWNGRADE
Target $20
ROTH
Neutral
MaxLinear downgraded to Neutral on near-term headwinds at Roth Capital
Roth Capital analyst Suji Desilva downgraded MaxLinear to Neutral from Buy and lowered his price target for the shares to $20 from $27. While the company remains positioned for the intermediate-term ramps of wireless infrastructure and connected home, near-term headwinds will impact its outlook, Desilva tells investors in a research note. The analyst believes China infrastructure concerns, a step back in multimedia over coax alliance connectivity demand and continued terrestrial tuner demand softness will limit upside in shares of MaxLinear in the short term. He will look for improving visibility prior to getting more aggressive with the stock.
06/29/18
NEED
06/29/18
NO CHANGE
Target $22
NEED
Buy
MaxLinear price target lowered to $22 from $27 at Needham
Needham analyst N. Quinn Bolton lowered his price target on MaxLinear to $22, saying the company is "hitting air pockets" in its cable data business amid transition issues between DOCSIS 3.0 and DOCSIS 3.1. Bolton states that the purchases of the former are down as OEMs look to reduce their inventory levels, while the ramp of the latter is taking longer and is now expected to start in Q4. The analyst keeps his Buy rating on MaxLinear longer term, noting that the DOCSIS weakness is already reflected in the price after the recent selloff.
07/12/18
BNCH
07/12/18
NO CHANGE
BNCH
Buy
Marvell, Ceva, MaxLinear stand to benefit from ZTE ban ending, says Benchmark
After the U.S. announced it has signed an escrow agreement with ZTE (ZTCOY) that should lift the supplier ban and allow the company to resume operations, Benchmark analyst Gary Mobley identified Ceva (CEVA), Marvell Technology (MRVL) and MaxLinear (MXL) as the stocks that he covers that have the most to gain from the lifting of the ZTE shipment ban. He maintains Buy ratings on all three suppliers.
07/18/18
DBAB
07/18/18
NO CHANGE
Target $19
DBAB
Hold
MaxLinear Q2 likely to be at lower end of guidance, says Deutsche Bank
Deutsche Bank analyst Ross Seymore believes headwinds within MaxLinear's (MXL) Connected Home segment are likely to yield Q2 results toward the lower end of guidance and Q3 revenues that are likely to slightly decline quarter-over-quarter. Further, the analyst believes the transition from DOCSIS 3.0 to DOCSIS 3.1 has been delayed at Arris (ARRS), MaxLinear's largest customer, thereby creating an additional headwind for Q2 and Q3. Seymore lowered his estimates for MaxLinear and expects the stock to remain range-bound. The analyst cut his price target for the stock to $19 from $21 and keeps a Hold rating on the name.

TODAY'S FREE FLY STORIES

ARGX

Argenx

$102.30

-0.94 (-0.91%)

, ORTX

Orchard Therapeutics

$15.00

-0.01 (-0.07%)

05:49
12/17/18
12/17
05:49
12/17/18
05:49
Recommendations
Argenx, Orchard Therapeutics analyst commentary  »

Goldman starts Argenx at…

ARGX

Argenx

$102.30

-0.94 (-0.91%)

ORTX

Orchard Therapeutics

$15.00

-0.01 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$172.80

-3.07 (-1.75%)

05:48
12/17/18
12/17
05:48
12/17/18
05:48
Periodicals
Malaysian authorities file criminal charges against Goldman Sachs, WSJ says »

Malaysia's attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALKS

Alkermes

$32.78

-1 (-2.96%)

05:47
12/17/18
12/17
05:47
12/17/18
05:47
Conference/Events
Alkermes management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

  • 31

    Jan

LULU

Lululemon

$119.13

-1.08 (-0.90%)

05:42
12/17/18
12/17
05:42
12/17/18
05:42
Upgrade
Lululemon rating change  »

Lululemon upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

  • 15

    Jan

AXON

Axovant Sciences

$1.01

-0.12 (-10.62%)

05:36
12/17/18
12/17
05:36
12/17/18
05:36
Upgrade
Axovant Sciences rating change  »

Axovant Sciences upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPI

SPI Energy

$1.19

-0.02 (-1.65%)

05:36
12/17/18
12/17
05:36
12/17/18
05:36
Hot Stocks
SPI Energy receives delinquency notice from Nasdaq »

SPI Energy announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

$0.00

(0.00%)

05:35
12/17/18
12/17
05:35
12/17/18
05:35
Hot Stocks
Bombardier to supply a further 20 FLEXITY trams to Karlsruhe »

Global mobility solution…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THC

Tenet

$21.24

-2.25 (-9.58%)

05:32
12/17/18
12/17
05:32
12/17/18
05:32
Downgrade
Tenet rating change  »

Tenet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMR

Emerson

$60.45

-0.29 (-0.48%)

05:31
12/17/18
12/17
05:31
12/17/18
05:31
Downgrade
Emerson rating change  »

Emerson downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MFA

MFA Financial

$6.98

-0.01 (-0.14%)

05:27
12/17/18
12/17
05:27
12/17/18
05:27
Upgrade
MFA Financial rating change  »

MFA Financial upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$66.24

-1.04 (-1.55%)

05:27
12/17/18
12/17
05:27
12/17/18
05:27
Hot Stocks
Incyte, Innovent announce strategic collaboration, licensing agreement »

Incyte and Innovent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

CSL

Carlisle

$96.53

-1.69 (-1.72%)

05:26
12/17/18
12/17
05:26
12/17/18
05:26
Upgrade
Carlisle rating change  »

Carlisle upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

05:25
12/17/18
12/17
05:25
12/17/18
05:25
Hot Stocks
Roche SMA treatment risdiplam granted PRIME designation by EMA »

Roche announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Dec

  • 18

    Mar

SMG

Scotts Miracle-Gro

05:25
12/17/18
12/17
05:25
12/17/18
05:25
Upgrade
Scotts Miracle-Gro rating change  »

Scotts Miracle-Gro…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MFA

MFA Financial

$6.98

-0.01 (-0.14%)

05:24
12/17/18
12/17
05:24
12/17/18
05:24
Upgrade
MFA Financial rating change  »

MFA Financial upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGI

Triumph Group

$13.23

0.13 (0.99%)

05:18
12/17/18
12/17
05:18
12/17/18
05:18
Upgrade
Triumph Group rating change  »

Triumph Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYB

LyondellBasell

$82.34

-1.35 (-1.61%)

05:16
12/17/18
12/17
05:16
12/17/18
05:16
Upgrade
LyondellBasell rating change  »

LyondellBasell upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EC

Ecopetrol

$18.36

-0.33 (-1.77%)

, YPF

YPF

$14.38

0.03 (0.21%)

05:11
12/17/18
12/17
05:11
12/17/18
05:11
Recommendations
Ecopetrol, YPF, Petrobras analyst commentary  »

Ecopetrol price target…

EC

Ecopetrol

$18.36

-0.33 (-1.77%)

YPF

YPF

$14.38

0.03 (0.21%)

PBR

Petrobras

$13.40

-0.235 (-1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALK

Alaska Air

$62.29

0.96 (1.57%)

05:04
12/17/18
12/17
05:04
12/17/18
05:04
Recommendations
Alaska Air analyst commentary  »

Alaska Air called a top…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVYA

Avaya

$17.58

-0.14 (-0.79%)

04:59
12/17/18
12/17
04:59
12/17/18
04:59
Initiation
Avaya initiated  »

Avaya initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARGX

Argenx

$102.30

-0.94 (-0.91%)

04:57
12/17/18
12/17
04:57
12/17/18
04:57
Initiation
Argenx initiated  »

Argenx initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORTX

Orchard Therapeutics

$15.00

-0.01 (-0.07%)

04:56
12/17/18
12/17
04:56
12/17/18
04:56
Upgrade
Orchard Therapeutics rating change  »

Orchard Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHW

Sherwin-Williams

$385.73

-0.075 (-0.02%)

04:55
12/17/18
12/17
04:55
12/17/18
04:55
Upgrade
Sherwin-Williams rating change  »

Sherwin-Williams upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACHN

Achillion

$3.12

0.035 (1.14%)

04:55
12/17/18
12/17
04:55
12/17/18
04:55
Conference/Events
Achillion to hold a conference call »

Dr. Stephen Zelenkofske,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

MDP

Meredith

$53.26

-0.54 (-1.00%)

04:55
12/17/18
12/17
04:55
12/17/18
04:55
Conference/Events
Meredith management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.